BCL2 and mantle cell lymphoma: The efficacy of obataclax, a BH3 mimetic inhibitor of anti-apoptotic Bcl-2 proteins, which demonstrated synergy with bortezomib in preclinical models, was studied in a phase 1–2 trial in association with bortezomib for 13 R/R MCL patients.